X-Chem, Inc. entered a multi-target collaboration with Pfizer for the potential development of several programs for the treatment of inflammatory and orphan diseases. X-Chem will apply its discovery engine, which leverages a high diversity DNA-encoded small molecule library to seek the identification of novel leads for undisclosed Pfizer programs. Pfizer has an exclusive option to license any compounds generated under the collaboration. Financial terms were not disclosed.   “The use of ultra-lar...